Trial Profile

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dendritic cell vaccines (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Pharmacodynamics; Therapeutic Use
Acronyms NATASHA trial

03 Mar 2025 Planned End Date changed from 31 Jan 2025 to 1 Oct 2026.
03 Mar 2025 Planned primary completion date changed from 31 Jan 2025 to 1 Oct 2025.
08 Feb 2024 Planned End Date changed from 1 Oct 2025 to 31 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com